What is the treatment for desquamative inflammatory vaginitis (DIV)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

Desquamative inflammatory vaginitis (DIV) should be treated with clindamycin 2% vaginal cream applied once daily for 14 days, followed by maintenance therapy 2-3 times weekly for 4-6 weeks, as this regimen has been shown to dramatically relieve symptoms in 86% of patients within 3 weeks, as reported in the study by 1.

Treatment Overview

The treatment of DIV typically involves the use of topical anti-inflammatory agents, such as clindamycin or hydrocortisone, to reduce inflammation and alleviate symptoms.

  • Clindamycin 2% vaginal cream is a commonly recommended treatment option, applied once daily for 14 days, followed by maintenance therapy 2-3 times weekly for 4-6 weeks.
  • Alternatively, 2% intravaginal hydrocortisone can be used with the same regimen, as both medications have been shown to be effective in treating DIV, as noted in the study by 2.
  • For severe cases, a combination of both medications may be necessary, as suggested by the study by 1.

Diagnostic Considerations

Before starting treatment, it is essential to confirm the diagnosis of DIV through vaginal pH and microscopy, as DIV typically presents with a pH >4.5 and increased parabasal cells with neutrophils on wet mount, as reported in the study by 3.

  • Patients should be advised to avoid sexual intercourse during treatment or use condoms, and to complete the full course even if symptoms improve quickly.
  • Treatment success is indicated by resolution of symptoms (discharge, burning, irritation) and normalization of vaginal flora on follow-up examination.

Recurrence and Maintenance Therapy

Recurrence is common in DIV, so patients should be monitored and may require intermittent maintenance therapy, as noted in the study by 4.

  • The study by 1 found that 53 patients experienced clinical remission, but 17 (32%) relapsed within 6 weeks, highlighting the need for ongoing monitoring and maintenance therapy.
  • The study by 2 also noted that maintenance treatment should be considered, as relapse is common in DIV.

References

Research

Desquamative inflammatory vaginitis.

Best practice & research. Clinical obstetrics & gynaecology, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.